Business Standard

The New Drugs Bill: A missed opportunity for reforms in Ayush

The Bill takes regressive steps on the issue of drug safety

Image
Premium

Dinesh ThakurPrashant Reddy T
Over the past decade, the practice of traditional medicine in India has been plagued by scandals ranging from misleading advertising to the adulteration of drugs with chemical painkillers and heavy metals.

The recently unveiled New Drugs, Cosmetics and Medical Devices Bill, 2022, presented an opportunity to reform the law on this aspect but unfortunately the drafters of the Bill have largely stayed away from significant reform.  

Some history may help in setting the context for the challenges in regulating the Ayush industry. In 1940, when the parliament enacted the Drugs Act, the definition of “drugs” in that law excluded Ayurvedic
Disclaimer: These are personal views of the writer. They do not necessarily reflect the opinion of www.business-standard.com or the Business Standard newspaper

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in